Status:
COMPLETED
A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Coronary Heart Disease
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This study will assess the safety, tolerability and efficacy of RO4607381 in patients with coronary heart disease (CHD) or CHD risk equivalents. Patients will be randomized to receive either RO4607381...
Eligibility Criteria
Inclusion
- adult patients, 18-75 years of age;
- CHD or CHD risk equivalent;
- appropriately treated for accepted LDL-C level.
Exclusion
- treatment with drugs raising HDL-C (eg niacin, fibrates);
- uncontrolled hypertension;
- recent (within 3 months) clinically significant coronary events, transient ischemic attacks or cerebrovascular accident;
- severe anemia;
- poorly controlled diabetes.
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
476 Patients enrolled
Trial Details
Trial ID
NCT00655538
Start Date
February 1 2008
End Date
May 1 2010
Last Update
January 2 2020
Active Locations (23)
Enter a location and click search to find clinical trials sorted by distance.
1
Feldkirch, Austria, 6800
2
Paris, France, 75908
3
Bonn, Germany, 53127
4
Dortmund, Germany, 44137